These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32586373)

  • 1. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.
    Krushkal J; Silvers T; Reinhold WC; Sonkin D; Vural S; Connelly J; Varma S; Meltzer PS; Kunkel M; Rapisarda A; Evans D; Pommier Y; Teicher BA
    Clin Epigenetics; 2020 Jun; 12(1):93. PubMed ID: 32586373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
    Polley E; Kunkel M; Evans D; Silvers T; Delosh R; Laudeman J; Ogle C; Reinhart R; Selby M; Connelly J; Harris E; Fer N; Sonkin D; Kaur G; Monks A; Malik S; Morris J; Teicher BA
    J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27247353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
    Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
    Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
    [No Abstract]   [Full Text] [Related]  

  • 4. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines.
    Vural S; Palmisano A; Reinhold WC; Pommier Y; Teicher BA; Krushkal J
    Clin Epigenetics; 2021 Mar; 13(1):49. PubMed ID: 33676569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
    Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11.
    Yin YP; Ma LY; Cao GZ; Hua JH; Lv XT; Lin WC
    Acta Pharmacol Sin; 2022 Aug; 43(8):2119-2127. PubMed ID: 34893686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.
    Tahir SK; Wass J; Joseph MK; Devanarayan V; Hessler P; Zhang H; Elmore SW; Kroeger PE; Tse C; Rosenberg SH; Anderson MG
    Mol Cancer Ther; 2010 Mar; 9(3):545-57. PubMed ID: 20179162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.
    Teicher BA; Silvers T; Selby M; Delosh R; Laudeman J; Ogle C; Reinhart R; Parchment R; Krushkal J; Sonkin D; Rubinstein L; Morris J; Evans D
    Cancer Med; 2017 Aug; 6(8):1952-1964. PubMed ID: 28766886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of glucocorticoid receptor expression by DNA methylation prevents glucocorticoid induced apoptosis in human small cell lung cancer cells.
    Kay P; Schlossmacher G; Matthews L; Sommer P; Singh D; White A; Ray D
    PLoS One; 2011; 6(10):e24839. PubMed ID: 21984896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
    Chowdhury A; Chowdhury S; Tsai MY
    Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
    Luszczek W; Cheriyath V; Mekhail TM; Borden EC
    Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A framework for identification of actionable cancer genome dependencies in small cell lung cancer.
    Sos ML; Dietlein F; Peifer M; Schöttle J; Balke-Want H; Müller C; Koker M; Richters A; Heynck S; Malchers F; Heuckmann JM; Seidel D; Eyers PA; Ullrich RT; Antonchick AP; Vintonyak VV; Schneider PM; Ninomiya T; Waldmann H; Büttner R; Rauh D; Heukamp LC; Thomas RK
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):17034-9. PubMed ID: 23035247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.
    Jayanthan A; Hofmann B; Meier-Stephenson V; Perinpanayagam M; Dunn SE; Boklan J; Trippett TM; Truong TH; Narendran A
    J Pediatr Hematol Oncol; 2019 Aug; 41(6):e359-e370. PubMed ID: 30702467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
    Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
    Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.